All News

At 1 month, the mean decrease in the OAB-Q symptom severity subscale score was -31.2 in the 1-injection cohort vs -39.5 in the 10-injection cohort.

Patients with higher baseline HEI and E-HEI scores were less likely to experience grade reclassification.

The cystoscopy solution was granted a CE mark for regulatory clearance in Europe in October 2023.

The trial is comparing the diagnostic performance of 61Cu-NODAGA-PSMA I&T with that of 18F-piflufolastat.

The codes will go into effect on January 1, 2026.

None of the videos mentioned the long-term impact of exogenous testosterone on spermatogenesis.

The decision to withdraw sacituzumab govitecan from the market was made in consultation with the US FDA following negative data from the phase 3 TROPiCS-04 trial.

Almost all studies (93.5%) reported an improvement in validated patient-reported outcomes following treatment.

SMSNA 2024 abstract data show shockwave therapies and platelet-rich plasma, either alone or in combination, may be promising treatments for ED.

68.8% of patients had at least a 30% improvement in ventral curvature from baseline.

“The take-home message…is it doesn't matter whether you put the reservoir in the ectopic location or the prevesical location. Patients tend to be satisfied in both locations,” said Mohit Khera, MD, MBA, MPH.

The investigators reported a significantly greater prevalence of ED in men with BPH (P < .0001).

“Allowing these women to have a fulfilling life after cancer is one of the best things we can do as physicians,” says Talia A. Helman, MD.

For the survey question “Do 5-ARIs reduce serum PSA?” 8 (9.4%) respondents said “no” and 25 (29.4%) said “not sure.”

Data from a Mayo Clinic study show, despite some reports of discomfort and dissatisfaction, a majority of patients receiving penile prosthesis are satisfied 1 year in.

New research better defines the link between cardiovascular disease risk and prevalence of ED per serum ceramide levels.

Data from a new SMSNA 2024 abstract show an association between significantly high BMI and risk of azoospermia and oligospermia.

Following use of MED3000, the investigators reported significant improvements in all 5 SEP questions in both patients and partners over the course of the 12 weeks.

The investigators reported a significant improvement in IPSS, from 21.9 at baseline to 12.6 at 4 years.

“Initiating oral TU therapy with Kyzatrex at 400 mg BID is safe and effective in achieving therapeutic serum testosterone levels," wrote the authors.

Overall, 4 of 5 patients with low-grade disease who received bel-sar with light activation achieved a complete clinical response.

The investigators found that only 2 (1.4%) urology programs and 12 (5.3%) OB/GYN programs included female sexual dysfunction content.

“In the absence of infection, [drain and retain] is a safe strategy without further complications compared to the primary groups," said Thairo Pereira, MD.

“Before and after implant, we noted a statistically significant increase in both the length and the girth,” said Peter J. Arnold, MD.

At 5 years, 95.8% of patients in the SBRT arm were free from biochemical or clinical failure compared with 94.6% of patients in the control radiotherapy arm.

Data from the EMPIRE-2 trial also showed that 18F-fluciclovine resulted in significantly more boosts to the prostate bed.

The target action date for the application is June 13, 2025.

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that we can further analyze through empirical studies," says Francesca A. Williamson, PhD.

Overall, 15/16 patients had a true positive scan based on confirmatory imaging and/or biopsy, equating to a PPV of 93.75%.

According to iota Biosciences, the device is “designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by underactive bladder.”